300030.SHE Guangzhou Improve Med Instrument
- Market cap
- CNY 2.13B
- P/E
- 230.0x
- P/B
- 3.54x
- ROE
- 3.9%
- Dividend yield
- 0.26%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300030.SHE undervalued?
Graham numberThe Graham number of Guangzhou Improve Med Instrument cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Guangzhou Improve Med Instrument fundamental analysis
No fundamental analysis for Guangzhou Improve Med Instrument yet.
Guangzhou Improve Med Instrument stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Guangzhou Improve Med Instrument
Improve Medical Instruments Co., Ltd. engages in the provision of relevant technologies, products, and services for clinical laboratory and clinical nursing in China and internationally. It provides clinical laboratory products comprising feces and thrombosis viscoelastic analysis systems; and automatic biosafety decappers; and Q-VELOX, an intelligent molecular diagnostic workstation. The company also offers specimen processing equipment, including evacuated blood collection…
Full company profileGuangzhou Improve Med Instrument financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Guangzhou Improve Med Instrument annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 517M | 550M | 550M | 575M | 919M | 800M | 711M | 645M | 581M | 486M | 485M |
| Gross Profit | 240M | 245M | 215M | 256M | 420M | 309M | 236M | 230M | 213M | 209M | 211M |
| Operating Income | 24.8M | 16.9M | -144M | 37.6M | 166M | 29.9M | -213M | -40.8M | -117M | 41.9M | 69.6M |
| EBITDA | 96.4M | 81.6M | -79.6M | 103M | 228M | 90.3M | -155M | 8.93M | -73.9M | 61.8M | 39.4M |
| Net Income | 30.5M | 11.2M | -137M | 26.0M | 163M | 18.6M | -198M | -63.2M | -118M | 14.5M | 25.2M |
| EPS | 0.10 | 0.04 | -0.44 | 0.08 | 0.53 | 0.06 | -0.64 | -0.20 | -0.38 | 0.05 | 0.08 |
| Balance Sheet | |||||||||||
| Total Assets | 1.47B | 1.75B | 1.51B | 1.51B | 1.74B | 1.83B | 1.56B | 1.43B | 1.24B | 1.03B | 929M |
| Total Liabilities | 516M | 782M | 696M | 669M | 742M | 795M | 738M | 664M | 600M | 372M | 261M |
| Shareholders' Equity | 944M | 955M | 811M | 836M | 1,000M | 1.00B | 784M | 723M | 607M | 620M | 639M |
| Cash & Short-term Investments | 128M | 271M | 234M | 250M | 272M | 346M | 224M | 238M | 248M | 160M | 115M |
| Total Debt | 347M | 600M | 500M | 471M | 443M | 525M | 426M | 365M | 336M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 23.2M | 142M | 56.0M | 49.2M | 141M | 172M | 42.5M | 79.9M | 81.8M | 110M | - |
| Capital Expenditure | 26.4M | 96.0M | 50.4M | 54.4M | 56.8M | 71.1M | 58.0M | 43.7M | 51.3M | 24.1M | 31.1M |
| Free Cash Flow | -3.21M | 46.2M | 5.64M | -5.28M | 84.5M | 101M | -15.6M | 36.2M | 30.6M | 85.8M | 67.2M |
| Ratios | |||||||||||
| ROE | 3.2% | 1.2% | -16.9% | 3.1% | 16.3% | 1.9% | -25.3% | -8.7% | -19.4% | 2.3% | 3.9% |
| ROA | 2.1% | 0.6% | -9.1% | 1.7% | 9.3% | 1.0% | -12.7% | -4.4% | -9.5% | 1.4% | 2.7% |
| Net Profit Margin | 5.9% | 2.0% | -24.9% | 4.5% | 17.7% | 2.3% | -27.9% | -9.8% | -20.3% | 3.0% | 5.2% |
| Debt to Equity | 0.37x | 0.63x | 0.62x | 0.56x | 0.44x | 0.52x | 0.54x | 0.51x | 0.55x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Guangzhou Improve Med Instrument dividends
- Dividend yield
- 0.26%
- Forward dividend
- -
- Payout ratio
- 37.8%
- Ex-dividend date
- Jul 6, 2022
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 5.50M | 0.02 | 37.8% |
| 2024 | CNY 12.0M | 0.04 | - |
| 2023 | CNY 15.9M | 0.05 | - |
| 2022 | CNY 12.4M | 0.04 | - |
| 2021 | CNY 9.88M | 0.03 | 53.2% |
| 2020 | CNY 26.8M | 0.09 | 16.5% |
| 2019 | CNY 26.1M | 0.08 | 100.4% |
| 2018 | CNY 30.7M | 0.10 | - |
| 2017 | CNY 13.4M | 0.05 | 120.1% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 20:10 on Apr 25, 2014.
Who owns Guangzhou Improve Med Instrument
- Insiders 37.35%
- Institutions 3.60%
- Public & others 59.05%
- Shares outstanding 309M
- Free float 221M
Guangzhou Improve Med Instrument company profile
- Company name
- Guangzhou Improve Med Instrument
- Ticker
- 300030.SHE
- ISIN
- CNE100000JL3
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Dec 25, 2009
- Sector
- Healthcare
- Industry
- Life Sciences Tools & Services
- Employees
- 632
- Fiscal year end
- December
- Address
- No. 102, Kaiyuan Avenue, Guangzhou, China, 510530
- Phone
- 86 20 3231 2610
- Website
- improve-medical.com
About Guangzhou Improve Med Instrument
Improve Medical Instruments Co., Ltd. engages in the provision of relevant technologies, products, and services for clinical laboratory and clinical nursing in China and internationally. It provides clinical laboratory products comprising feces and thrombosis viscoelastic analysis systems; and automatic biosafety decappers; and Q-VELOX, an intelligent molecular diagnostic workstation. The company also offers specimen processing equipment, including evacuated blood collection systems, evacuated blood collection tubes, multi-sample needles, blood collection sets, tourniquets and disposable tourniquets, urine collection systems, and holders under IMPROVACUTER brand name; and IMPROMINI capillary blood collection systems, IMPROSWAB microbiological transportation systems, IMPRONURSE infusion pumps and syringe pumps, LONGX urine analysis systems, in-vitro diagnostic reagents, IMPROSAFE safety blood collection needles, IMPROVE sharps containers, liquid biopsy pre-analytical systems, etc. In addition, it provides clinical nursing products, including automatic, handheld, pulsewave, and smart wireless blood pressure monitors; and intelligent management solutions, such as blood collection tube preparation systems, friendly graphic user interfaces, intelligent sorters, multi-function blood collection tables, intelligent queue systems, urine collection tube preparation systems, automatic tube packer systems, and consumable labels, as well as CryoMax vials and liquid nitrogen freezing storage boxes. The company was formerly known as Guangzhou Improve Medical Instruments Co., Ltd. and changed its name to Improve Medical Instruments Co., Ltd. in December 2021. The company was founded in 1996 and is headquartered in Guangzhou, China.
Guangzhou Improve Med Instrument management
7- Dr. Hong Yu YanCFO & Deputy GM · born 1964
- Mr. Guangcheng JiangDeputy GM & Non-Independent Director · born 1968
- Mr. Wei YuBoard Secretary & Non Independent Director · born 1986
- Mr. Ke TianDeputy General Manager · born 1975
- Mr. Zhou WeiDeputy General Manager · born 1979
- Ning LiChief Accounting Officer
- Chuan Rong QianVice President